Tuberculosis Vaccine Research and Development

Guest Editor:

Prof. Dr. Mark Chambers
Faculty of Health and Medical Sciences, University of Surrey, Guildford GU2 7XH, UK

Deadline for manuscript submissions:
closed (3 July 2020)

Message from the Guest Editor

Dear Colleagues,

Tuberculosis is one of the biggest threats to the health, welfare, and productivity of humans and animals globally. It causes more human deaths than any other infectious organism.

This Special Issue will highlight current research activities in the research and development of tuberculosis vaccines. We particularly encourage submissions relating to vaccine formulation (such as DNA, subunit, recombinant, and nano- and micro-particles) and different delivery modalities (such as mucosal, aerosol, transdermal) and the evaluation of their safety and efficacy in animal models and target species.

Prof. Mark Chambers
Guest Editor

Special Issue

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us